HomeDMD

DMD

What Is Exon Deletion? Understanding Exon Deletions in Duchenne Muscular Dystrophy

What is exon deletion, and why does it matter in Duchenne muscular dystrophy? An exon deletion occurs when one or more sections of a gene are missing, potentially affecting how the body produces an essential protein. In DMD, these deletions occur in the DMD gene, which contains the instructions...

Phases of Clinical Trials: Complete Drug Development Guide

Understanding the phases of clinical trials can help families make sense of how a potential medicine moves from laboratory research toward possible approval and wider patient access. When families hear that a treatment is in Phase 1, Phase 2, or Phase 3, the terminology can be confusing. Each stage...
spot_img

Keep exploring

Investigational New Drug (IND) Clearance for Duchenne Muscular Dystrophy: Process, Trials & Future Therapies

The pathway to Investigational New Drug (IND) clearance for Duchenne muscular dystrophy is one...

Gowers Sign in Duchenne Muscular Dystrophy: Early Symptoms, Diagnosis & Clinical Meaning

Gowers signs in Duchenne muscular dystrophy and the Gowers maneuver are among the earliest...

What is Exon Skipping Therapy in Duchenne Muscular Dystrophy and How Does it Work?

What is exon skipping therapy in DMD, and how does it work in Duchenne...

6 Early Signs of Duchenne Muscular Dystrophy Every Parent Should Know Today

Signs of Duchenne muscular dystrophy (DMD) are often subtle in early childhood but progressively...

How Does Duchenne Muscular Dystrophy Affect the Brain? Cognitive, Behavioral & Neurological Insights

How does Duchenne muscular dystrophy affect the brain? This question is increasingly important as...

Life Expectancy in Duchenne Muscular Dystrophy: The Impact of Care and Treatment on Outcomes

Understanding Life Expectancy life expectancy in duchenne muscular dystrophy is one of the most...

Duchenne vs. Becker Muscular Dystrophy: A Complete Comparison Guide

Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) are both genetic disorders that...

Genetic Counseling in Duchenne Muscular Dystrophy: Carrier Testing, Risk Assessment, and Prenatal Diagnosis

Genetic Counseling in Duchenne Muscular Dystrophy (DMD) plays a crucial role in helping patients...

Types of Genetic Variants in Duchenne Muscular Dystrophy: Deletions, Duplications, and Point Mutations

Duchenne muscular dystrophy (DMD) is one of the most severe inherited neuromuscular disorders affecting...

Genetic Causes of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle weakness...

Duchenne Carriers Explained: How DMD Affects Girls and Women

Duchenne carriers play a critical role in the understanding and management of Duchenne Muscular...

Duchenne Muscular Dystrophy (DMD): 108 Frequently Asked Questions (Complete Guide 2026)

Duchenne muscular dystrophy (DMD) is a rare, progressive genetic disorder that causes muscle weakness...

Latest articles

Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production

Entrada Therapeutics has announced positive initial results from its Exon 45 Skipping Study, ELEVATE-45-201,...

Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study

Entrada Therapeutics has received clearance to test the highest dose in its Exon 44...

Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne

Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne...

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Capricor Therapeutics has reported new results from the HOPE-3 study evaluating Deramiocel in people...

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Ractigen Therapeutics has presented positive first-in-human data for RAG-18 (NCT07282652), an investigational treatment for...

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Entrada Therapeutics’ ENTR-601-44 is an investigational therapy designed for patients with Duchenne muscular dystrophy...

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

NS Pharma’s brogidirsen (NS-089/NCNP-02) is an investigational therapy for Duchenne muscular dystrophy (DMD) designed...

ELEVIDYS WMS 2026 Data: What They Show—and What They Don’t

Sarepta Therapeutics has presented new data on ELEVIDYS (delandistrogene moxeparvovec) at the 2026 World...